IDEAS home Printed from https://ideas.repec.org/r/aea/jeclit/v56y2018i2p397-449.html

Economics of the Pharmaceutical Industry

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Dubois, Pierre & Moisson, Paul-Henri & Tirole, Jean, 2022. "The Economics of Transferable Patent Extensions," TSE Working Papers 22-1377, Toulouse School of Economics (TSE), revised Dec 2022.
  2. Kurt R. Brekke & Dag Morten Dalen & Odd Rune Straume, 2022. "The price of cost-effectiveness thresholds," NIPE Working Papers 5/2022, NIPE - Universidade do Minho.
  3. Nakamura, Hiroshi & Wakutsu, Naohiko, 2020. "Reducing Reimbursement Drug Price Risk to Enhance R&D Incentives without Raising Drug Prices/Expenditures: Implications of Simulations Based on Questionnaire Survey of Pharmaceutical Companies in Japan," Health Policy, Elsevier, vol. 124(7), pages 714-720.
  4. Enes Işık & Özgür Orhangazi, 2022. "Profitability and drug discovery," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 31(4), pages 891-904.
  5. Hu, Bill & Hwang, Joon Ho & Jiang, Christine & Washam, Jim & Zeng, Li, 2022. "Down to the cents: The case of international drug prices," Finance Research Letters, Elsevier, vol. 46(PA).
  6. Manuel Acosta & Daniel Coronado & Jennifer Medina, 2024. "Effects of co-patenting across national boundaries on patent quality. An exploration in pharmaceuticals," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 33(2), pages 248-281, February.
  7. Kamphorst, Jurjen & Karamychev, Vladimir A., 2025. "Going through the roof: On prices for drugs sold through insurance," Games and Economic Behavior, Elsevier, vol. 151(C), pages 218-242.
  8. Kortelainen, Mika & Markkanen, Jaakko & Toivanen, Otto & Siikanen, Markku, 2023. "The Effects of Price Regulation on Pharmaceutical Expenditure and Availability," CEPR Discussion Papers 18497, Centre for Economic Policy Research.
  9. repec:osf:socarx:z5mf6_v2 is not listed on IDEAS
  10. Mauro Caselli & Arpita Chatterjee & Shengyu Li, 2023. "Productivity and Quality of Multi-product Firms," Discussion Papers 2023-10, School of Economics, The University of New South Wales.
  11. Suppliet, Moritz, 2020. "Umbrella branding in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 73(C).
  12. Jakub P. Hlávka & Jeffrey C. Yu & Dana P. Goldman & Darius N. Lakdawalla, 2021. "The economics of alternative payment models for pharmaceuticals," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(4), pages 559-569, June.
  13. repec:osf:socarx:z5mf6_v1 is not listed on IDEAS
  14. Zhang, Siyu & Huang, Yuexin & Luo, Danglun, 2026. "Industry regulation and firm innovation: Evidence from national centralized drug procurement policy in China," Economic Analysis and Policy, Elsevier, vol. 89(C), pages 421-441.
  15. Voss, Philipp S.R., 2022. "Innovation Performance in Healthcare M&A: An Empirical Analysis," Junior Management Science (JUMS), Junior Management Science e. V., vol. 7(4), pages 1164-1192.
  16. Arnold, Denis G. & Amato, Louis H. & Troyer, Jennifer L. & Stewart, Oscar Jerome, 2022. "Innovation and misconduct in the pharmaceutical industry," Journal of Business Research, Elsevier, vol. 144(C), pages 1052-1063.
  17. Ute Laermann-Nguyen & Martin Backfisch, 2021. "Innovation crisis in the pharmaceutical industry? A survey," SN Business & Economics, Springer, vol. 1(12), pages 1-37, December.
  18. Geng, Hao & Shi, Ce Matthew, 2024. "Health policy, price regulation, and innovation: Evidence from China’s vaccine industry," Journal of Development Economics, Elsevier, vol. 167(C).
  19. Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," Research Papers 3889, Stanford University, Graduate School of Business.
  20. Venkatanarayana Motkuri & Rudra Narayan Mishra, 2020. "Pharmaceutical Market and Drug Price Policy in India," Review of Development and Change, , vol. 25(1), pages 30-53, June.
  21. Fabian Gaessler & Stefan Wagner, 2022. "Patents, Data Exclusivity, and the Development of New Drugs," The Review of Economics and Statistics, MIT Press, vol. 104(3), pages 571-586, May.
  22. Beth Woods & James Lomas & Mark Sculpher & Helen Weatherly & Karl Claxton, 2024. "Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required," Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 804-819, April.
  23. Gamba, S.; & Pertile, P.; & Righetti, G.;, 2022. "Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany," Health, Econometrics and Data Group (HEDG) Working Papers 22/20, HEDG, c/o Department of Economics, University of York.
  24. Difei Geng & Kamal Saggi, 2023. "Optimal price regulations in international pharmaceutical markets with generic competition," World Scientific Book Chapters, in: Kamal Saggi (ed.), Technology Transfer, Foreign Direct Investment, and the Protection of Intellectual Property in the Global Economy, chapter 18, pages 415-433, World Scientific Publishing Co. Pte. Ltd..
  25. Dubois, Pierre, 2025. "Pharmaceutical Regulation and Incentives for Innovation in an International Perspective," CEPR Discussion Papers 20728, Centre for Economic Policy Research.
  26. Dominique Foray & Gaetan de Rassenfosse & George Abi Younes & Charles Ayoubi & Omar Ballester & Gabriele Cristelli & Matthias van den Heuvel & Ling Zhou & Gabriele Pellegrino & Patrick Gaulé & Elizab, 2020. "COVID-19: Insights from Innovation Economists," Working Papers 10, Chair of Science, Technology, and Innovation Policy.
    • Younes, George Abi & Ayoubi, Charles & Ballester, Omar & Cristelli, Gabriele & de Rassenfosse, Gaetan & Foray, Dominique & Gaule, Patrick & Pellegrino, Gabriele & van den Heuvel, Matthias & Webster, B, 2020. "COVID-19_Insights from Innovation Economists," SocArXiv b5zae, Center for Open Science.
  27. Gloria Allione & Raffaello Bronzini & Claire Giordano, 2020. "Recent export developments in the pharmaceutical sector in Italy and in the Lazio region," Questioni di Economia e Finanza (Occasional Papers) 566, Bank of Italy, Economic Research and International Relations Area.
  28. Byrski, Dennis & Wang, Lucy Xiaolu, 2025. "Marketing authorization and strategic patenting: Evidence from pharmaceuticals," Journal of Public Economics, Elsevier, vol. 247(C).
  29. Kurt R. Brekke & Dag Morten Dalen & Odd Rune Straume, 2024. "Competing with precision: incentives for developing predictive biomarker tests," Scandinavian Journal of Economics, Wiley Blackwell, vol. 126(1), pages 60-97, January.
  30. Dubois, Pierre & Majewska, Gosia, 2022. "Mergers and Advertising in the Pharmaceutical Industry," CEPR Discussion Papers 17658, Centre for Economic Policy Research.
  31. Levaggi, Laura & Levaggi, Rosella, 2024. "Competition, value-based prices and incentives to research personalised drugs," Socio-Economic Planning Sciences, Elsevier, vol. 93(C).
  32. Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 90(C).
  33. Miozza, Mario & Lombardo, Salvatore M. & Galvagno, Marco & Magni, Luca, 2026. "Bridging the digital divide in the pharmaceutical industry: A future research agenda," Social Science & Medicine, Elsevier, vol. 389(C).
  34. Georges Siotis & Carmine Ornaghi & Micael Castanheira, 2023. "Evolving market boundaries and competition policy enforcement in the pharmaceutical industry," European Journal of Law and Economics, Springer, vol. 55(2), pages 313-348, April.
  35. Stacciarini, João Henrique Santana, 2024. "Power, Disputes, and Geopolitics in the Pharmaceutical Sector," SocArXiv z5mf6, Center for Open Science.
  36. Gianluca Antonecchia & Ajay Bhaskarabhatla & Enrico Pennings, 2024. "Bargaining Power and Quantity Discounts to Retailers: Evidence from India’s Pharmaceutical Industry," Tinbergen Institute Discussion Papers 24-048/VII, Tinbergen Institute.
  37. Tobias Basse & Christoph Schwarzbach & J.-Matthias Schulenburg, 2023. "Dividend policy issues in the European pharmaceutical industry: new empirical evidence," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(5), pages 803-816, July.
  38. Pierre Dubois & Ariel Pakes, 2026. "Pharmaceutical Advertising in Dynamic Equilibrium," Working Papers hal-05573625, HAL.
  39. Gianfranco Marotta & Phillipe Krahnhof & Cam-Duc Au, 2022. "A Critical Analysis of Budgeting Processes from the Pharmaceutical Industry and Beyond," Journal of Applied Finance & Banking, SCIENPRESS Ltd, vol. 12(3), pages 1-3.
  40. Zhang, Xuan & Nie, Huihua, 2021. "Public health insurance and pharmaceutical innovation: Evidence from China," Journal of Development Economics, Elsevier, vol. 148(C).
  41. Payel Sadhukhan & Samrat Gupta & Subhasis Ghosh & Tanujit Chakraborty, 2026. "Demystifying the trend of the healthcare index: Is historical price a key driver?," Papers 2601.14062, arXiv.org.
  42. Sara Boni & Francesco Ravazzolo, 2022. "A Structural Analysis of Unemployment-Generating Supply Shocks with an Application to the US Pharmaceutical Industry," BEMPS - Bozen Economics & Management Paper Series BEMPS94, Faculty of Economics and Management at the Free University of Bozen.
  43. Dubois, Pierre & Magnac, Thierry, 2024. "Optimal intertemporal curative drug expenses: The case of hepatitis C in France," Journal of Health Economics, Elsevier, vol. 94(C).
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.